Literature DB >> 24555441

Activation of the chromosome 19q microRNA cluster in sporadic and androgenetic-biparental mosaicism-associated hepatic mesenchymal hamartoma.

Raj P Kapur1, Jessica E Berry, Karen D Tsuchiya, Kent E Opheim.   

Abstract

Recurrent genetic alterations found in hepatic mesenchymal hamartoma include either androgenetic-biparental mosaicism or chromosomal rearrangements involving chromosome 19q13.4, in the vicinity of the chromosome 19q microRNA cluster (C19MC). Abnormal activation of C19MC, which is subject to paternal imprinting and is normally expressed only in placenta, could account for both genetic associations because androgenetic cells carry only paternal chromosomes. In this study, a 4.2-Mb deletion involving the 5'-end of C19MC was detected in a sporadic mesenchymal hamartoma by chromosomal microarray. Fluorescence in situ hybridization studies showed that the deletion localized to mesenchymal cells in the stroma of the hamartoma. Quantitative real-time polymerase chain reaction analysis of this tumor, 9 other sporadic hepatic mesenchymal hamartomas, and 3 hamartomas associated with androgenetic-biparental mosaicism demonstrated C19MC microRNA expression in all but 2 sporadic cases, with no significant expression in control liver. The findings support a pathogenetic model for mesenchymal hamartoma as a consequence of "ectopic" activation of C19MC in hepatic stroma, due to either chromosomal rearrangements or paternal uniparental disomy.

Entities:  

Keywords:  androgenetic; imprinting; mesenchymal hamartoma; microRNA; uniparental disomy

Mesh:

Substances:

Year:  2014        PMID: 24555441     DOI: 10.2350/13-12-1415-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  8 in total

1.  Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma.

Authors:  Graham M Strub; Andrew L Kirsh; Mark E Whipple; Winston P Kuo; Rachel B Keller; Raj P Kapur; Mark W Majesky; Jonathan A Perkins
Journal:  JCI Insight       Date:  2016-09-08

2.  The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss.

Authors:  Bhuvana A Setty; Goodwin G Jinesh; Michael Arnold; Fredrik Pettersson; Chia-Ho Cheng; Ling Cen; Sean J Yoder; Jamie K Teer; Elsa R Flores; Damon R Reed; Andrew S Brohl
Journal:  PLoS Genet       Date:  2020-04-20       Impact factor: 5.917

Review 3.  Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review.

Authors:  Sebastiao N Martins-Filho; Juan Putra
Journal:  Hepat Oncol       Date:  2020-04-07

Review 4.  ETMR: a tumor entity in its infancy.

Authors:  Sander Lambo; Katja von Hoff; Andrey Korshunov; Stefan M Pfister; Marcel Kool
Journal:  Acta Neuropathol       Date:  2020-06-29       Impact factor: 17.088

Review 5.  Genomic alterations in thymoma-molecular pathogenesis?

Authors:  Felicitas Oberndorfer; Leonhard Müllauer
Journal:  J Thorac Dis       Date:  2020-12       Impact factor: 3.005

Review 6.  DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma.

Authors:  Iván A González; Douglas R Stewart; Kris Ann P Schultz; Amanda P Field; D Ashley Hill; Louis P Dehner
Journal:  Mod Pathol       Date:  2021-10-01       Impact factor: 7.842

7.  Clinicopathological study of hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a single center study from Iran.

Authors:  Parham Habibzadeh; Mohaddese Ansari Asl; Hamid Reza Foroutan; Ali Bahador; Mohammad Hossein Anbardar
Journal:  Diagn Pathol       Date:  2021-06-24       Impact factor: 2.644

8.  A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.

Authors:  Milan Radovich; Jeffrey P Solzak; Bradley A Hancock; Madison L Conces; Rutuja Atale; Ryan F Porter; Jin Zhu; Jarret Glasscock; Kenneth A Kesler; Sunil S Badve; Bryan P Schneider; Patrick J Loehrer
Journal:  Br J Cancer       Date:  2016-01-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.